|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oberstein PE and Olive KP: Pancreatic
cancer: Why is it so hard to treat? Therap Adv Gastroenterol.
6:321–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M,
Liu L, Liu C, Xu J, Gao YT, Zheng Y, et al: Cancer statistics:
Current diagnosis and treatment of pancreatic cancer in Shanghai,
China. Cancer Lett. 346:273–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Provenzano PP, Cuevas C, Chang AE, Goel
VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma
ablates physical barriers to treatment of pancreatic ductal
adenocarcinoma. Cancer Cell. 21:418–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Z, Ma Q, Li P, Sha H, Li X and Xu J:
Aberrant expression of CXCR4 and β-catenin in pancreatic cancer.
Anticancer Res. 33:4103–4110. 2013.PubMed/NCBI
|
|
9
|
Hrckulak D, Kolar M, Strnad H and Korinek
V: TCF/LEF transcription factors: An update from the internet
resources. Cancers. 8(pii): E702016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu L, Zhi Q, Shen M, Gong FR, Zhou BP,
Lian L, Shen B, Chen K, Duan W, Wu MY, et al: FH535, a β-catenin
pathway inhibitor, represses pancreatic cancer xenograft growth and
angiogenesis. Oncotarget. 7:47145–47162. 2016.PubMed/NCBI
|
|
11
|
Behrens J, von Kries JP, Kühl M, Bruhn L,
Wedlich D, Grosschedl R and Birchmeier W: Functional interaction of
beta-catenin with the transcription factor LEF-1. Nature.
382:638–642. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shang S, Hua F and Hu ZW: The regulation
of β-catenin activity and function in cancer: Therapeutic
opportunities. Oncotarget. 8:33972–33989. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duarte JG and Blackburn JM: Advances in
the development of human protein microarrays. Expert Rev
Proteomics. 14:627–641. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato Y, Miya M, Fukunaga T, Sado T and
Iwasaki W: MitoFish and MiFish pipeline: A mitochondrial genome
database of fish with an analysis pipeline for environmental DNA
metabarcoding. Mol Biol Evol. 35:1553–1555. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Győrffy B, Pongor L, Bottai G, Li X,
Budczies J, Szabó A, Hatzis C, Pusztai L and Santarpia L: An
integrative bioinformatics approach reveals coding and non-coding
gene variants associated with gene expression profiles and outcome
in breast cancer molecular subtypes. Br J Cancer. 118:1107–1114.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arensman MD, Telesca D, Lay AR, Kershaw
KM, Wu N, Donahue TR and Dawson DW: The CREB-binding protein
inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer
Ther. 13:2303–2314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu MY, Liang RR, Chen K, Shen M, Tian YL,
Li DM, Duan WM, Gui Q, Gong FR, Lian L, et al: FH535 inhibited
metastasis and growth of pancreatic cancer cells. Onco Targets
Ther. 8:1651–1670. 2015.PubMed/NCBI
|
|
18
|
Kanehisa M, Sato Y, Kawashima M, Furumichi
M and Tanabe M: KEGG as a reference resource for gene and protein
annotation. Nucleic Acids Res. 44(D1): D457–D462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ilic M and Ilic I: Epidemiology of
pancreatic cancer. World J Gastroenterol. 22:9694–9705. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mohammed S, Van Buren G II and Fisher WE:
Pancreatic cancer: Advances in treatment. World J Gastroenterol.
20:9354–9360. 2014.PubMed/NCBI
|
|
22
|
López-Casas PP and López-Fernández LA:
Gene-expression profiling in pancreatic cancer. Expert Rev Mol
Diagn. 10:591–601. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Duan C, Liu Y, Lu L, Cai R, Xue H, Mao X,
Chen C, Qian R, Zhang D and Shen A: CDK14 contributes to reactive
gliosis via interaction with cyclin Y in rat model of spinal cord
injury. J Mol Neurosci. 57:571–579. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hamilton T and Schifrin BS: Delayed
cesarean section in preeclampsia with placental abruption and fetal
distress. J Perinatol. 11:182–185. 1991.PubMed/NCBI
|
|
25
|
Li S, Song W, Jiang M, Zeng L, Zhu X and
Chen J: Phosphorylation of cyclin Y by CDK14 induces its
ubiquitination and degradation. FEBS Lett. 588:1989–1996. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang L, Zhu J, Huang H, Yang Q, Cai J,
Wang Q, Zhu J, Shao M, Xiao J, Cao J, et al: PFTK1 promotes gastric
cancer progression by regulating proliferation, migration and
invasion. PLoS One. 10:e01404512015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang B, Zou A, Ma L, Chen X, Wang L, Zeng
X and Tan T: miR-455 inhibits breast cancer cell proliferation
through targeting CDK14. Eur J Pharmacol. 807:138–143. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prakash N and Wurst W: A Wnt signal
regulates stem cell fate and differentiation in vivo. Neurodegener
Dis. 4:333–338. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Davidson G and Niehrs C: Emerging links
between CDK cell cycle regulators and Wnt signaling. Trends Cell
Biol. 20:453–460. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Jia Y, Fei C, Song X and Li L:
Activation/proliferation-associated protein 2 (Caprin-2) positively
regulates CDK14/Cyclin Y-mediated lipoprotein receptor-related
protein 5 and 6 (LRP5/6) constitutive phosphorylation. J Biol Chem.
291:26427–26434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng L, Zhou Z and He Z: Knockdown of
PFTK1 inhibits tumor cell proliferation, invasion and
epithelial-to-mesenchymal transition in pancreatic cancer. Int J
Clin Exp Pathol. 8:14005–14012. 2015.PubMed/NCBI
|
|
32
|
Gu X, Wang Y, Wang H, Ni Q, Zhang C, Zhu
J, Huang W, Xu P, Mao G and Yang S: Upregulated PFTK1 promotes
tumor cell proliferation, migration, and invasion in breast cancer.
Med Oncol. 32:1952015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Du B, Zhang P, Tan Z and Xu J: MiR-1202
suppresses hepatocellular carcinoma cells migration and invasion by
targeting cyclin dependent kinase 14. Biomed Pharmacother.
96:1246–1252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang W, Liu R, Tang C, Xi Q, Lu S, Chen
W, Zhu L, Cheng J, Chen Y, Wang W, et al: PFTK1 regulates cell
proliferation, migration and invasion in epithelial ovarian cancer.
Int J Biol Macromol. 85:405–416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang LH, Yin AA, Cheng JX, Huang HY, Li
XM, Zhang YQ, Han N and Zhang X: TRIM24 promotes glioma progression
and enhances chemoresistance through activation of the PI3K/Akt
signaling pathway. Oncogene. 34:600–610. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xue D, Zhang X, Zhang X, Liu J, Li N, Liu
C, Liu Y and Wang P: Clinical significance and biological roles of
TRIM24 in human bladder carcinoma. Tumour Biol. 36:6849–6855. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miao ZF, Wang ZN, Zhao TT, Xu YY, Wu JH,
Liu XY, Xu H, You Y and Xu HM: TRIM24 is upregulated in human
gastric cancer and promotes gastric cancer cell growth and
chemoresistance. Virchows Arch. 466:525–532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fang Z, Deng J, Zhang L, Xiang X, Yu F,
Chen J, Feng M and Xiong J: TRIM24 promotes the aggression of
gastric cancer via the Wnt/β-catenin signaling pathway. Oncol Lett.
13:1797–1806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang S, Minter LC, Stratton SA, Yang P,
Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, et al:
TRIM24 suppresses development of spontaneous hepatic lipid
accumulation and hepatocellular carcinoma in mice. J Hepatol.
62:371–379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bazar L, Harris V, Sunitha I, Hartmann D
and Avigan M: A transactivator of c-myc is coordinately regulated
with the proto-oncogene during cellular growth. Oncogene.
10:2229–2238. 1995.PubMed/NCBI
|
|
41
|
Zhang J and Chen QM: Far upstream element
binding protein 1: A commander of transcription, translation and
beyond. Oncogene. 32:2907–2916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kozma L, Kiss I, Nagy A, Szakáll S and
Ember I: Investigation of c-myc and K-ras amplification in renal
clear cell adenocarcinoma. Cancer Lett. 111:127–131. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lian Y, Niu X, Cai H, Yang X, Ma H, Ma S,
Zhang Y and Chen Y: Clinicopathological significance of c-MYC in
esophageal squamous cell carcinoma. Tumour Biol. 39:1–7. 2017.
View Article : Google Scholar
|
|
44
|
Rabenhorst U, Beinoraviciute-Kellner R,
Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J,
Chung HJ, Levens DL and Zörnig M: Overexpression of the far
upstream element binding protein 1 in hepatocellular carcinoma is
required for tumor growth. Hepatology. 50:1121–1129. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Malz M, Weber A, Singer S, Riehmer V,
Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, et
al: Overexpression of far upstream element binding proteins: A
mechanism regulating proliferation and migration in liver cancer
cells. Hepatology. 50:1130–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang L, Zhu JY, Zhang JG, Bao BJ, Guan CQ,
Yang XJ, Liu YH, Huang YJ, Ni RZ and Ji LL: Far upstream
element-binding protein 1 (FUBP1) is a potential c-Myc regulator in
esophageal squamous cell carcinoma (ESCC) and its expression
promotes ESCC progression. Tumour Biol. 37:4115–4126. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Khageh Hosseini S, Kolterer S, Steiner M,
von Manstein V, Gerlach K, Trojan J, Waidmann O, Zeuzem S, Schulze
JO, Hahn S, et al: Camptothecin and its analog SN-38, the active
metabolite of irinotecan, inhibit binding of the transcriptional
regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.
Biochem Pharmacol. 146:53–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Venturutti L, Cordo Russo RI, Rivas MA,
Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M,
Proietti CJ, Yankilevich P, et al: MiR-16 mediates trastuzumab and
lapatinib response in ErbB-2-positive breast and gastric cancer via
its novel targets CCNJ and FUBP1. Oncogene. 35:6189–6202. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Disteldorf EM, Krebs CF, Paust HJ, Turner
JE, Nouailles G, Tittel A, Meyer-Schwesinger C, Stege G, Brix S,
Velden J, et al: CXCL5 drives neutrophil recruitment in
TH17-mediated GN. J Am Soc Nephrol. 26:55–66. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mei J, Liu Y, Dai N, Hoffmann C, Hudock
KM, Zhang P, Guttentag SH, Kolls JK, Oliver PM, Bushman FD and
Worthen GS: Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and
neutrophil homeostasis in mice. J Clin Invest. 122:974–986. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nouailles G, Dorhoi A, Koch M, Zerrahn J,
Weiner J III, Faé KC, Arrey F, Kuhlmann S, Bandermann S, Loewe D,
et al: CXCL5-secreting pulmonary epithelial cells drive destructive
neutrophilic inflammation in tuberculosis. J Clin Invest.
124:1268–1282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH,
Wang Z, Huang XW, Fan J and Zhou J: Overexpression of CXCL5
mediates neutrophil infiltration and indicates poor prognosis for
hepatocellular carcinoma. Hepatology. 56:2242–2254. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Speetjens FM, Kuppen PJ, Sandel MH, Menon
AG, Burg D, van de Velde CJ, Tollenaar RA, de Bont HJ and
Nagelkerke JF: Disrupted expression of CXCL5 in colorectal cancer
is associated with rapid tumor formation in rats and poor prognosis
in patients. Clin Cancer Res. 14:2276–2284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zheng J, Zhu X and Zhang J: CXCL5
knockdown expression inhibits human bladder cancer T24 cells
proliferation and migration. Biochem Biophys Res Commun. 446:18–24.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu
C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5
promotes human colorectal cancer metastasis through activation of
the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer.
16:702017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW,
Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to
epithelial-mesenchymal transition of HCC cells through activating
PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 358:124–135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Huang P, Xu X, Wang L, Zhu B, Wang X and
Xia J: The role of EGF-EGFR signalling pathway in hepatocellular
carcinoma inflammatory microenvironment. J Cell Mol Med.
18:218–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Johnson KM, Phan TTN, Albertolle ME and
Guengerich FP: Human mitochondrial cytochrome P450 27C1 is
localized in skin and preferentially desaturates trans-retinol to
3,4-dehydroretinol. J Biol Chem. 292:13672–13687. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Enright JM, Toomey MB, Sato SY, Temple SE,
Allen JR, Fujiwara R, Kramlinger VM, Nagy LD, Johnson KM, Xiao Y,
et al: Cyp27c1 red-shifts the spectral sensitivity of
photoreceptors by converting vitamin A1 into A2. Curr Biol.
25:3048–3057. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Morshedian A, Toomey MB, Pollock GE,
Frederiksen R, Enright JM, McCormick SD, Cornwall MC, Fain GL and
Corbo JC: Cambrian origin of the CYP27C1-mediated vitamin
A1-to-A2 switch, a key mechanism of
vertebrate sensory plasticity. R Soc Open Sci. 4:1703622017.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
